{"id":745119,"date":"2015-09-18T14:00:00","date_gmt":"2015-09-18T14:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-of-phase-2-study-of-mercks-investigational-beta-lactamase-inhibitor-relebactam-presented-at-icaac-icc-2015\/"},"modified":"2025-11-07T01:24:57","modified_gmt":"2025-11-07T06:24:57","slug":"results-of-phase-2-study-of-mercks-investigational-beta-lactamase-inhibitor-relebactam-presented-at-icaac-icc-2015","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-of-phase-2-study-of-mercks-investigational-beta-lactamase-inhibitor-relebactam-presented-at-icaac-icc-2015\/","title":{"rendered":"Results of Phase 2 Study of Merck\u2019s Investigational Beta-Lactamase Inhibitor Relebactam Presented at ICAAC\/ICC 2015"},"content":{"rendered":"<p class=\"bwalignc\">       Company Initiates Pivotal Phase 3 Studies Evaluating Relebactam in        Combination with Imipenem\/Cilastatin for Treatment of Serious Bacterial        Infections     <\/p>\n<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that a Phase 2 study of relebactam, the company\u2019s<br \/>\n      investigational beta-lactamase inhibitor for the treatment, in<br \/>\n      combination with imipenem\/cilastatin (an approved carbapenem<br \/>\n      antibiotic), of complicated intra-abdominal infections, met its primary<br \/>\n      endpoint, and that Merck is now initiating pivotal Phase 3 studies. In<br \/>\n      the Phase 2 study, relebactam in combination with imipenem\/cilastatin<br \/>\n      demonstrated noninferiority in the percentage of microbiologically<br \/>\n      evaluable patients with favorable clinical response at the end of<br \/>\n      intravenous therapy compared to imipenem\/cilastatin alone. The addition<br \/>\n      of relebactam is designed to restore activity of imipenem against<br \/>\n      certain imipenem-resistant strains of Gram-negative bacteria, including <i>Pseudomonas<br \/>\n      aeruginosa<\/i> and <i>Klebsiella pneumoniae<\/i> carbapenemase<br \/>\n      (KPC)-producing Enterobacteriaceae.\n    <\/p>\n<p>\n      The results were presented at the Interscience Conference of<br \/>\n      Antimicrobial Agents and Chemotherapy (ICAAC) and International Congress<br \/>\n      of Chemotherapy and Infection (ICC) joint meeting in San Diego, Sept.<br \/>\n      17-21.\n    <\/p>\n<p>\n      \u201cNew medicines are urgently needed to address the growing threat of<br \/>\n      antibiotic-resistant bacteria,\u201d said Dr. Nicholas Kartsonis, associate<br \/>\n      vice president, infectious disease clinical research, Merck Research<br \/>\n      Laboratories. \u201cWe look forward to advancing our Phase 3 clinical program<br \/>\n      evaluating relebactam, in combination with imipenem\/cilastatin, for use<br \/>\n      in the treatment of several complicated Gram-negative bacterial<br \/>\n      infections, and to continue to build on Merck&#8217;s commitment to infectious<br \/>\n      diseases.\u201d\n    <\/p>\n<p>\n      In this multicenter, double-blind Phase 2 study, 351 adult patients with<br \/>\n      complicated intra-abdominal infections, most commonly complicated<br \/>\n      appendicitis (53%) and complicated cholecystitis (17%), were randomized<br \/>\n      to receive either relebactam 250mg, relebactam 125mg or placebo, each<br \/>\n      given intravenously in combination with imipenem\/cilastatin 500mg every<br \/>\n      six hours for 4 to 14 days. The percentage of microbiologically<br \/>\n      evaluable patients with favorable clinical response at the end of<br \/>\n      intravenous therapy, the primary efficacy endpoint, was similar across<br \/>\n      treatment groups: relebactam 250mg (96.3%) (n=83), relebactam 125mg<br \/>\n      (98.8%) (n=87) and placebo (95.2%) (n=85).\n    <\/p>\n<p>\n      Safety analysis focused on adverse events occurring while on intravenous<br \/>\n      study therapy or during the 14 days following the end of therapy. The<br \/>\n      most common adverse events (nausea, diarrhea and vomiting) occurred at<br \/>\n      similar rates across treatment groups: relebactam 250mg (6.8%, 6.0%,<br \/>\n      6.0%), relebactam 125mg (7.8%, 6.0%, 7.8%) and placebo (7.0%, 4.4%,<br \/>\n      2.6%), respectively.\n    <\/p>\n<p>\n      <b>Phase 3 Clinical Program of Imipenem\/Cilastatin\/Relebactam Initiated<\/b>\n    <\/p>\n<p>\n      Based in part on the results of this Phase 2 study, Merck is planning to<br \/>\n      initiate two pivotal Phase 3 clinical studies of relebactam with<br \/>\n      imipenem\/cilastatin given as a fixed-dose combination. A study comparing<br \/>\n      imipenem\/cilastatin\/relebactam to colistimethate sodium in combination<br \/>\n      with imipenem\/cilastatin for the treatment of imipenem-resistant<br \/>\n      bacterial infections, including those caused by<i> P. aeruginosa <\/i>and<br \/>\n      KPC-producing organisms, is currently recruiting patients. Infections<br \/>\n      evaluated in this study are hospital-acquired bacterial pneumonia,<br \/>\n      ventilator-associated bacterial pneumonia, complicated intra-abdominal<br \/>\n      infections and complicated urinary tract infections. (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT02452047%3Fterm%3Drelebactam%26rank%3D1&amp;esheet=51182634&amp;newsitemid=20150918005023&amp;lan=en-US&amp;anchor=www.ClinicalTrials.gov+Identifier%3A+NCT02452047&amp;index=1&amp;md5=ec005e661def663c96f83c0f65722d33\" rel=\"nofollow\">www.ClinicalTrials.gov<br \/>\n      Identifier: NCT02452047<\/a>)\n    <\/p>\n<p>\n      A second Phase 3 study, which will initiate later this year, will<br \/>\n      compare treatment with the fixed-dose combination of<br \/>\n      imipenem\/cilastatin\/relebactam to piperacillin\/tazobactam in patients<br \/>\n      with hospital-acquired and ventilator-associated bacterial pneumonia. (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT02493764%3Fterm%3Drelebactam%26rank%3D2&amp;esheet=51182634&amp;newsitemid=20150918005023&amp;lan=en-US&amp;anchor=www.ClinicalTrials.gov+Identifier%3A+NCT02493764&amp;index=2&amp;md5=0d0c81589a1d5c8fafc62d4ec14da81c\" rel=\"nofollow\">www.ClinicalTrials.gov<br \/>\n      Identifier: NCT02493764<\/a>)\n    <\/p>\n<p>\n      <b>About Relebactam<\/b>\n    <\/p>\n<p>\n      Relebactam is an investigational intravenous, class A and C,<br \/>\n      beta-lactamase inhibitor currently being evaluated in combination with<br \/>\n      imipenem\/cilastatin for the treatment of certain complicated<br \/>\n      Gram-negative bacterial infections. In preclinical studies, relebactam<br \/>\n      administered in combination with imipenem demonstrated antibacterial<br \/>\n      activity against a broad range of Gram-negative and<br \/>\n      beta-lactam-resistant pathogens. The U.S. Food and Drug Administration<br \/>\n      (FDA) has designated this combination as a Qualified Infectious Disease<br \/>\n      Product (QIDP) with designated Fast Track status for the treatment of<br \/>\n      hospital-acquired bacterial pneumonia, ventilator-associated bacterial<br \/>\n      pneumonia, complicated intra-abdominal infections and complicated<br \/>\n      urinary tract infections.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside of the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to healthcare through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51182634&amp;newsitemid=20150918005023&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=3&amp;md5=aff9635031b8ece07b4f56f2288344db\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fmerck&amp;esheet=51182634&amp;newsitemid=20150918005023&amp;lan=en-US&amp;anchor=Twitter&amp;index=4&amp;md5=226688e8525436697bdc4efabe255670\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51182634&amp;newsitemid=20150918005023&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=223703bff8b9b1df747fb63f83ea3a35\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51182634&amp;newsitemid=20150918005023&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=67f225ecb8b376fc6d42601e0554eed5\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2014 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51182634&amp;newsitemid=20150918005023&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=6c085903ef576363605c8c125860027e\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150918005023r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Doris Li, (908) 246-5701<br \/>Ian McConnell,        (973) 901-5722<br \/>or<br \/>Investor:<br \/>Teri Loxam, (908) 740-1986<br \/>Justin        Holko, (908) 740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Company Initiates Pivotal Phase 3 Studies Evaluating Relebactam in Combination with Imipenem\/Cilastatin for Treatment of Serious Bacterial Infections Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that a Phase 2 study of relebactam, the company\u2019s investigational beta-lactamase inhibitor for the treatment, in combination with imipenem\/cilastatin (an approved carbapenem antibiotic), of complicated intra-abdominal infections, met its primary endpoint, and that Merck is now initiating pivotal Phase 3 studies. In the Phase 2 study, relebactam in combination with imipenem\/cilastatin demonstrated noninferiority in the percentage of microbiologically evaluable patients with favorable clinical response at the end of intravenous therapy compared to imipenem\/cilastatin alone. The addition of relebactam is designed to restore activity of imipenem against certain imipenem-resistant strains of Gram-negative bacteria, including Pseudomonas aeruginosa and<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,56],"class_list":["post-745119","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Results of Phase 2 Study of Merck\u2019s Investigational Beta-Lactamase Inhibitor Relebactam Presented at ICAAC\/ICC 2015 - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-of-phase-2-study-of-mercks-investigational-beta-lactamase-inhibitor-relebactam-presented-at-icaac-icc-2015\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Results of Phase 2 Study of Merck\u2019s Investigational Beta-Lactamase Inhibitor Relebactam Presented at ICAAC\/ICC 2015 - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Company Initiates Pivotal Phase 3 Studies Evaluating Relebactam in Combination with Imipenem\/Cilastatin for Treatment of Serious Bacterial Infections Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that a Phase 2 study of relebactam, the company\u2019s investigational beta-lactamase inhibitor for the treatment, in combination with imipenem\/cilastatin (an approved carbapenem antibiotic), of complicated intra-abdominal infections, met its primary endpoint, and that Merck is now initiating pivotal Phase 3 studies. In the Phase 2 study, relebactam in combination with imipenem\/cilastatin demonstrated noninferiority in the percentage of microbiologically evaluable patients with favorable clinical response at the end of intravenous therapy compared to imipenem\/cilastatin alone. The addition of relebactam is designed to restore activity of imipenem against certain imipenem-resistant strains of Gram-negative bacteria, including Pseudomonas aeruginosa and\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-of-phase-2-study-of-mercks-investigational-beta-lactamase-inhibitor-relebactam-presented-at-icaac-icc-2015\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:24:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/results-of-phase-2-study-of-mercks-investigational-beta-lactamase-inhibitor-relebactam-presented-at-icaac-icc-2015\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/results-of-phase-2-study-of-mercks-investigational-beta-lactamase-inhibitor-relebactam-presented-at-icaac-icc-2015\\\/\",\"name\":\"Results of Phase 2 Study of Merck\u2019s Investigational Beta-Lactamase Inhibitor Relebactam Presented at ICAAC\\\/ICC 2015 - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2015-09-18T14:00:00+00:00\",\"dateModified\":\"2025-11-07T06:24:57+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/results-of-phase-2-study-of-mercks-investigational-beta-lactamase-inhibitor-relebactam-presented-at-icaac-icc-2015\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/results-of-phase-2-study-of-mercks-investigational-beta-lactamase-inhibitor-relebactam-presented-at-icaac-icc-2015\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/results-of-phase-2-study-of-mercks-investigational-beta-lactamase-inhibitor-relebactam-presented-at-icaac-icc-2015\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Results of Phase 2 Study of Merck\u2019s Investigational Beta-Lactamase Inhibitor Relebactam Presented at ICAAC\\\/ICC 2015\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Results of Phase 2 Study of Merck\u2019s Investigational Beta-Lactamase Inhibitor Relebactam Presented at ICAAC\/ICC 2015 - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-of-phase-2-study-of-mercks-investigational-beta-lactamase-inhibitor-relebactam-presented-at-icaac-icc-2015\/","og_locale":"en_US","og_type":"article","og_title":"Results of Phase 2 Study of Merck\u2019s Investigational Beta-Lactamase Inhibitor Relebactam Presented at ICAAC\/ICC 2015 - Merck.com","og_description":"Company Initiates Pivotal Phase 3 Studies Evaluating Relebactam in Combination with Imipenem\/Cilastatin for Treatment of Serious Bacterial Infections Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that a Phase 2 study of relebactam, the company\u2019s investigational beta-lactamase inhibitor for the treatment, in combination with imipenem\/cilastatin (an approved carbapenem antibiotic), of complicated intra-abdominal infections, met its primary endpoint, and that Merck is now initiating pivotal Phase 3 studies. In the Phase 2 study, relebactam in combination with imipenem\/cilastatin demonstrated noninferiority in the percentage of microbiologically evaluable patients with favorable clinical response at the end of intravenous therapy compared to imipenem\/cilastatin alone. The addition of relebactam is designed to restore activity of imipenem against certain imipenem-resistant strains of Gram-negative bacteria, including Pseudomonas aeruginosa and","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-of-phase-2-study-of-mercks-investigational-beta-lactamase-inhibitor-relebactam-presented-at-icaac-icc-2015\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:24:57+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-of-phase-2-study-of-mercks-investigational-beta-lactamase-inhibitor-relebactam-presented-at-icaac-icc-2015\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-of-phase-2-study-of-mercks-investigational-beta-lactamase-inhibitor-relebactam-presented-at-icaac-icc-2015\/","name":"Results of Phase 2 Study of Merck\u2019s Investigational Beta-Lactamase Inhibitor Relebactam Presented at ICAAC\/ICC 2015 - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2015-09-18T14:00:00+00:00","dateModified":"2025-11-07T06:24:57+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-of-phase-2-study-of-mercks-investigational-beta-lactamase-inhibitor-relebactam-presented-at-icaac-icc-2015\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-of-phase-2-study-of-mercks-investigational-beta-lactamase-inhibitor-relebactam-presented-at-icaac-icc-2015\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-of-phase-2-study-of-mercks-investigational-beta-lactamase-inhibitor-relebactam-presented-at-icaac-icc-2015\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Results of Phase 2 Study of Merck\u2019s Investigational Beta-Lactamase Inhibitor Relebactam Presented at ICAAC\/ICC 2015"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"498699e6-b278-4816-95d7-43765d7956b4","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Results-of-Phase-2-Study-of-Mercks-Investigational-Beta-Lactamase-Inhibitor-Relebactam-Presented-at-ICAACICC-2015-2015.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745119","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745119\/revisions"}],"predecessor-version":[{"id":3674600,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745119\/revisions\/3674600"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745119"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745119"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}